The Future of Cannabis Health Lies in Collaboration
Ryan Allway
March 22nd, 2018
Exclusive, News, Top News
Many physicians are hesitant to prescribe medical cannabis due to a lack of understanding about how it affects patients and what strains and dosages are appropriate. Without an effective feedback loop between patients and healthcare providers, the situation is unlikely to improve. The good news is that some companies are seeking to close the feedback loop.
Resolve Digital Health Inc.’s Resolve ONE™ smart inhaler represents a breakthrough in the medical cannabis industry and investors may want to take note sooner rather than later.
Click here to receive company updates and alerts regarding Resolve.
The Incomplete Feedback Loop
One of the issues facing physicians is the lack of accurate feedback and information from their patients. A doctor may prescribe a treatment, but once the patient leaves the office, the doctor has no idea whether the patient picks up the prescription or uses it as directed. Even in the best case scenario of perfect patient compliance, there is usually no communication about the patient’s experience while following the prescription. Is the treatment working? How does the patient feel? Is there a potentially better solution to be tried prior to the next scheduled visit? A system streamlining a patient/doctor feedback loop would go a long way toward making treatments as effective and responsive as possible for each individual.
Medical cannabis has been shown to effectively treat many conditions, but there are few robust clinical trials to guide physicians’ decisions. Without any clinical trials or shared data, many physicians have a hard time knowing which cannabis strains to prescribe to a patient. It’s also challenging to follow up with the patient over time to personalize the treatment. This incomplete feedback loop has become a major barrier for medical cannabis therapies.
Closing the Feedback Loop
Resolve Digital Health’s smart inhaler, the Resolve ONE™ is designed to close the feedback loop between patients and doctors by providing a tool that monitors treatment and shares data. In addition to providing a metered dose to the patient, the device captures data on medical conditions, prescriptions, family history, lifestyle, and effectiveness per dose. This information enables patients and their physicians to monitor efficacy and continuously improve treatment. The data is stored and, at the patient’s discretion, can be shared with doctors, pharmacists, and other caregivers, bringing collaborative healthcare to the cannabis industry. Doctors can see how a patient is responding to treatment and adjust as needed.
Doctors can also leverage data from one patient to inform how to better treat other patients. Rather than guessing what strains work best, they can look at their other patients and see that a certain strain and dosage tend to work best. This reduces the amount of trial-and-error involved when prescribing medical cannabis and helps improve the overall patient experience, while reducing the physician’s need to spend time trying to extract information from patients.
By bringing collaboration back to healthcare, the patient can be sure that they’re receiving the best possible treatment at all times.
Click here to receive company updates and alerts regarding Resolve.
Leveraging Consumer-Generated Data
Resolve’s long-term plans are to use the data generated from its Resolve ONE™ inhaler to help improve the medical cannabis industry on a large scale.
Patients will have the opportunity to anonymously share information about the medical condition for which they are being treated and which strains and doses worked best for them. Licensed producers can use this data to improve their product offerings and effectiveness. For instance, the data may show that one strain works better for opioid-replacement than another. The LP may decide to focus their growing efforts on the more effective strain and market that strain to patients and physicians based on the hard data. The same goes for specific concentrates of CBD, THC, and other cannabinoid compounds.
Healthcare industry partners can leverage the same data to aid research on the efficacy of specific strains’ medicinal value when conducting trials. There’s no doubt that clinical trials are needed to push the industry fully into mainstream medicine and the data collected from the Resolve ONE™ is a key step in that process. By identifying the most promising starting point, researchers can minimize trial-and-error and focus on developing optimal therapies.
Resolve Digital Health is also initiating its own clinical trial program in the hopes of pushing the industry forward. Utilizing the Resolve ONE™ inhaler, the company is investigating the efficacy of cannabis as a tool for pain management. The studies will examine cannabis as both a substitute for and an adjunct to opioid treatments. The company also plans to study cannabis as a treatment for a variety of other conditions, including sleep disorders, anxiety, depression, and PTSD.
Looking Ahead
Resolve Digital Health Inc.’s smart inhaler represents a breakthrough in the medical cannabis industry. With the potential to close the feedback loop, the device can help dramatically improve patient efficacy and make physicians more likely to prescribe the drug. The data generated from these activities can also help licensed producers optimize their growing and healthcare researchers optimize their clinical trials.
For more information, visit the company’s website at www.resolvedigitalhealth.com.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Rubicon Holdings, Inc., a Washington State corporation, is a cannabis company focused on the United States adult use and medical marijuana markets.
Women Grow was created to connect, educate, inspire and empower the next generation of cannabis industry leaders by creating programs, community and events for aspiring and current business executives.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
